Andere Sprachen Moleculin Biotech, Inc.

Aktien

A407S6

US60855D3098

MBRX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 26.04.2024			% 5 Tage	% 1. Jan.
4,63 ^USD	+7,47 %		-0,43 %	-64,04 %

28.03.	Transcript : Moleculin Biotech, Inc. - Special Call
27.03.	Sektor-Update: Aktien des Gesundheitswesens legen am späten Nachmittag zu	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

European Medicines Agency Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia	19.04.
Sector Update: Health Care Stocks Ease in Afternoon Trading	18.04.
Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU	18.04.
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)	18.04.
Top Premarket Decliners	16.04.
Moleculin to Present at the MedInvest Biotech & Pharma Investor Conference	28.03.
Moleculin to Participate in the Virtual Investor Lunch Break, the Moleculin Opportunity	28.03.
Sector Update: Health Care Stocks Advance Late Afternoon	27.03.
Sector Update: Health Care	27.03.
Moleculin Biotech Shares Rise Following Patent Announcement	27.03.
Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity	27.03.
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML	27.03.
Moleculin Reports Full Year 2023 Financial Results	25.03.
Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial	25.03.
Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial	25.03.
Moleculin Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22.03.
Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and Webcast	20.03.
North American Morning Briefing : Markets on Hold as Fed Decision Nears	20.03.
Moleculin Biotech to Effect 1-For-15 Reverse Stock Split to Regain Compliance	19.03.
Moleculin Announces Reverse Stock Split	19.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Moleculin Biotech, Inc.

Aktien

A407S6

US60855D3098

MBRX

Andere Sprachen

Filter